Related Experiment Videos
Quality Indicators in Endoscopic Ablation for Barrett's Esophagus
1Division of Gastroenterology and Hepatology, University of Colorado Anschutz Medical Campus, 1635 Aurora Court, Rm 2.031, Aurora, CO, 80045, USA.
Current Treatment Options in Gastroenterology
|April 20, 2017
Summary
Barrett's esophagus (BE) management uses endoscopic eradication therapy (EET) with radiofrequency ablation (RFA). This review focuses on quality indicators for EET in BE neoplasia, aiming for consistent practice integration.
Area of Science:
- Gastroenterology
- Oncology
- Medical Quality Improvement
Background:
- Barrett's esophagus (BE) is a premalignant condition for esophageal adenocarcinoma (EAC).
- Esophageal adenocarcinoma (EAC) has a poor prognosis.
- Endoscopic eradication therapy (EET) is the standard of care for BE with dysplasia and early neoplasia.
Purpose of the Study:
- To review the current status of quality indicators in EET for BE-related neoplasia.
- To discuss future steps for uniform incorporation of quality indicators into practice.
Main Methods:
- Review of current literature and guidelines on EET for BE.
- Analysis of quality indicators relevant to EET procedures.
- Discussion of value-based healthcare principles in relation to EET quality.
Main Results:
- EET, particularly radiofrequency ablation (RFA) after endoscopic mucosal resection (EMR), is effective for BE neoplasia.
- There is an increasing focus on quality indicators in healthcare, including EET.
- Uniform incorporation of quality indicators into practice is needed.
Conclusions:
- Quality indicators are crucial for standardizing and improving EET for BE-related neoplasia.
- Further efforts are required to ensure consistent implementation of these indicators in clinical practice.
- This will enhance patient care and outcomes in the management of BE.